Format

Send to

Choose Destination
J Viral Hepat. 2018 Mar;25(3):220-227. doi: 10.1111/jvh.12859.

Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era.

Author information

1
Johns Hopkins University School of Medicine, Baltimore, MD, USA.
2
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Abstract

The availability of effective, simple, well-tolerated oral direct-acting antiviral (DAA) hepatitis C regimens has raised optimism for hepatitis C virus (HCV) elimination at the population level. HCV reinfection in key populations such as people who inject drugs (PWID) and HIV-infected men who have sex with men (MSM) however threatens the achievement of this goal from a patient, provider and population perspective. The goal of this review was to synthesize our current understanding of estimated rates and factors associated with HCV reinfection. This review also proposes interventions to aid understanding of and reduce hepatitis C reinfection among PWID and HIV-infected MSM in the oral direct-acting antiviral era.

KEYWORDS:

hepatitis C; men who have sex with men; people who inject drugs; reinfection

PMID:
29316030
PMCID:
PMC5841922
DOI:
10.1111/jvh.12859
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center